Infusion of Apomorphine: Long-term Safety Study
Public ClinicalTrials.gov record NCT02339064. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available Therapy
Study identification
- NCT ID
- NCT02339064
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
- Industry
- Enrollment
- 99 participants
Conditions and interventions
Conditions
Interventions
- apomorphine infusion Drug
Drug
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2015
- Primary completion
- Nov 30, 2018
- Completion
- Nov 30, 2025
- Last update posted
- Jun 18, 2025
2015 – 2025
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | 85013 | — |
| Not listed | Loma Linda | California | 92354 | — |
| Not listed | Los Angeles | California | 90033 | — |
| Not listed | Los Angeles | California | 90095 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Englewood | Colorado | 80113 | — |
| Not listed | Boca Raton | Florida | 33486 | — |
| Not listed | Atlanta | Georgia | 30329 | — |
| Not listed | Augusta | Georgia | 30912 | — |
| Not listed | Chicago | Illinois | 60611 | — |
| Not listed | Chicago | Illinois | 60612 | — |
| Not listed | Kansas City | Kansas | 66160 | — |
| Not listed | West Bloomfield | Michigan | 48322 | — |
| Not listed | Albany | New York | 12208 | — |
| Not listed | Cincinnati | Ohio | 45219 | — |
| Portland VA Medical Center | Portland | Oregon | 97239 | — |
| Not listed | Philadelphia | Pennsylvania | 19107 | — |
| Not listed | Kirkland | Washington | 98034 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02339064, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 18, 2025 · Synced Apr 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02339064 live on ClinicalTrials.gov.